Pixyl has obtained 510(k) clearance from the Food and Drug Administration (FDA). NeuroTM, an adjunctive artificial intelligence (AI)-powered program, has the potential to enhance the detection and monitoring of patients with neurological conditions such as multiple sclerosis (MS) and Alzheimer’s disease through magnetic resonance imaging (MRI).
Pixyl boasts the capability to conduct automated MRI analyses within a brief timeframe of under five minutes. The software, developed by Pixyl, aims to aid in quantifying head region levels to facilitate early identification of atrophy and support in the process of differential diagnosis.
Dr. Lotfi Hacein-Bey highlights the significance of adjunctive AI in reinforcing radiology procedures for assessing individuals with neurological disorders.
Dr. Hacein-Bey, the Director of the Division of Neuroradiology at the University of California, Davis (UC Davis) School of Medicine in Sacramento, California, views the recent FDA approval of Pixyl’s software as a significant advancement towards enhancing the diagnosis, treatment, and long-term monitoring of neurodegenerative and neuroinflammatory conditions.
Pixyl reports a substantial increase in the utilization of the brain application since December 2022, with its usage expanding to over 12 countries.
